期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 16, 期 2, 页码 181-194出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.16.2.181
关键词
alvimopan; constipation; enteric nervous system; intestinal peristalsis; naloxone; N-methylnaltrexone; opioid peptides; opioid-induced bowel dysfunction; peripherally restricted opioid receptor antagonists; prokinetic effects
Opioid analgesics are the mainstay in the treatment of mode rate-to-severe pain, yet their use is frequently associated with adverse effects, the most common and debilitating being constipation. Opioid-induced motor stasis results from blockade of gastrointestinal peristalsis and fluid secretion, and reflects the action of the endogenous opioid system in the gut. Methylnaltrexone and alvimopan are new investigational drugs that selectively target peripheral p-opioid receptors because they are poorly absorbed in the intestine and do not enter the brain. Clinical studies have proved the concept that these drugs prevent opioid-induced bowel dysfunction without interfering with analgesia. As reviewed in this article, opioid receptor antagonists with a peripherally restricted site of action also hold therapeutic promise in postoperative ileus and chronic constipation due to the fact that they have been found to stimulate intestinal transit.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据